Akinlolu Oluwamisimi
Research Subjects
Akinlolu Oluwamisimi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ndidi Atasie Eboh
Department of Nursing Science, Stark State College, North Canton, OH, USA
2 shared publications - Adepeju Kafayat Olowookere
Department of Nanoscience, University of North Carolina at Greensboro, Greensboro, NC, USA
1 shared publication - Chidinma Lorretta Gab-Obinna
Biomedical Laboratory Science Department, Kingston University London, London, United Kingdom
1 shared publication - Chinaza Faith Ngwoke
School of Pharmacy and Health Science, United States International University Africa Nairobi, Kenya
1 shared publication - Daniel Obinna Eke
Department of Nursing, Myrtle E. and Earl E. Walker College of Health Professions Maryville University of St. Louis, St. Louis, MO, USA
1 shared publication Isaac Baiden
1 shared publication
Latest Publications
- 17 March 2026
- Published by IK Press in Journal of International Research in Medical and Pharmaceutical Sciences
- Vol. 21 (2) , 183-200
Use of Artificial Intelligence and Machine Learning in Rapid Drug Discovery and Pharmacovigilance
The increasing global burden of disease, rising research and development costs, and high attrition rates in pharmaceutical pipelines underscore the need for more efficient approaches to therapeutic development and drug safety monitoring. Artificial intelligence (AI) and machine learning (ML) have emerged as data-driven tools with the potential to improve multiple stages of the pharmaceutical lifecycle. This narrative review is designed to provide a structured and critical overview of the use of AI and ML in drug discovery and drug safety surveillance. A comprehensive literature search was performed to identify relevant studies using major electronic databases, with emphasis on publications from 1997 to March 2025. The studies were selected based on the inclusion criteria. The findings of the study show that AI and ML are being used in drug discovery, drug development, and drug safety surveillance. These technologies have the potential to provide predictive models, integrate heterogeneous biomedical data, and analyze real-world data to detect adverse drug reactions. Deep learning and natural language processing have been found to be useful tools to improve early risk detection. However, some limitations have also been found. These include the quality of the data, bias in AI and ML models, lack of interpretability of AI and ML models, lack of external validation, and lack of real-world implementation. These limitations need to be addressed to make AI and ML more useful tools for drug discovery and drug safety surveillance. Overall, while AI and ML offer meaningful opportunities to enhance drug discovery and pharmacovigilance, their impact remains dependent on rigorous validation, improved data governance, and alignment with clinical and regulatory frameworks. Continued research and context-specific implementation strategies will be essential to support their effective and equitable integration into pharmaceutical research and healthcare systems.
- 17 March 2026
- Published by IK Press in Journal of International Research in Medical and Pharmaceutical Sciences
- Vol. 21 (2) , 183-200
Use of Artificial Intelligence and Machine Learning in Rapid Drug Discovery and Pharmacovigilance
The increasing global burden of disease, rising research and development costs, and high attrition rates in pharmaceutical pipelines underscore the need for more efficient approaches to therapeutic development and drug safety monitoring. Artificial intelligence (AI) and machine learning (ML) have emerged as data-driven tools with the potential to improve multiple stages of the pharmaceutical lifecycle. This narrative review is designed to provide a structured and critical overview of the use of AI and ML in drug discovery and drug safety surveillance. A comprehensive literature search was performed to identify relevant studies using major electronic databases, with emphasis on publications from 1997 to March 2025. The studies were selected based on the inclusion criteria. The findings of the study show that AI and ML are being used in drug discovery, drug development, and drug safety surveillance. These technologies have the potential to provide predictive models, integrate heterogeneous biomedical data, and analyze real-world data to detect adverse drug reactions. Deep learning and natural language processing have been found to be useful tools to improve early risk detection. However, some limitations have also been found. These include the quality of the data, bias in AI and ML models, lack of interpretability of AI and ML models, lack of external validation, and lack of real-world implementation. These limitations need to be addressed to make AI and ML more useful tools for drug discovery and drug safety surveillance. Overall, while AI and ML offer meaningful opportunities to enhance drug discovery and pharmacovigilance, their impact remains dependent on rigorous validation, improved data governance, and alignment with clinical and regulatory frameworks. Continued research and context-specific implementation strategies will be essential to support their effective and equitable integration into pharmaceutical research and healthcare systems.
- 1 January 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (1) , 310-329
Integrating Social Determinants of Health into Precision Medicine: A Critical Review of a Missing Link in Personalized Healthcare
Background: Precision medicine has transformed healthcare through advances in genomics, biomarkers, and artificial intelligence. However, its predominant focus on biological determinants reflects a reductionist approach that inadequately captures the broader social and environmental factors influencing health outcomes. Aim: This review aims to critically examine the limitations of current precision medicine frameworks, particularly the exclusion of social determinants of health (SDOH), and to explore the need for a more integrative, context-aware approach to personalized healthcare. Methods: A critical narrative review was conducted using literature from PubMed, Scopus, and Web of Science, covering publications between 2015 and 2025. Relevant studies addressing precision medicine, SDOH, health disparities, and artificial intelligence were selected based on predefined inclusion criteria and analyzed using thematic synthesis. Results: The findings reveal that current precision medicine models are constrained by biological reductionism, data bias, algorithmic inequities, and fragmented data systems. The exclusion of SDOH limits predictive accuracy, reduces the effectiveness of personalized interventions, and contributes to persistent health disparities. Emerging evidence highlights the potential of integrating artificial intelligence and digital health technologies with social and behavioral data to enhance context-aware care. Conclusion: Precision medicine, as currently practiced, is biologically precise but contextually incomplete. Integrating SDOH into precision medicine frameworks is essential for improving clinical effectiveness, promoting health equity, and ensuring real-world applicability. A shift toward an integrative model that combines biological, social, and behavioral determinants is necessary to achieve truly personalized and patient-centered healthcare.
- 1 January 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (1) , 310-329
Integrating Social Determinants of Health into Precision Medicine: A Critical Review of a Missing Link in Personalized Healthcare
Background: Precision medicine has transformed healthcare through advances in genomics, biomarkers, and artificial intelligence. However, its predominant focus on biological determinants reflects a reductionist approach that inadequately captures the broader social and environmental factors influencing health outcomes. Aim: This review aims to critically examine the limitations of current precision medicine frameworks, particularly the exclusion of social determinants of health (SDOH), and to explore the need for a more integrative, context-aware approach to personalized healthcare. Methods: A critical narrative review was conducted using literature from PubMed, Scopus, and Web of Science, covering publications between 2015 and 2025. Relevant studies addressing precision medicine, SDOH, health disparities, and artificial intelligence were selected based on predefined inclusion criteria and analyzed using thematic synthesis. Results: The findings reveal that current precision medicine models are constrained by biological reductionism, data bias, algorithmic inequities, and fragmented data systems. The exclusion of SDOH limits predictive accuracy, reduces the effectiveness of personalized interventions, and contributes to persistent health disparities. Emerging evidence highlights the potential of integrating artificial intelligence and digital health technologies with social and behavioral data to enhance context-aware care. Conclusion: Precision medicine, as currently practiced, is biologically precise but contextually incomplete. Integrating SDOH into precision medicine frameworks is essential for improving clinical effectiveness, promoting health equity, and ensuring real-world applicability. A shift toward an integrative model that combines biological, social, and behavioral determinants is necessary to achieve truly personalized and patient-centered healthcare.